Metocar

Metoprolol Tartrate, the active ingredient in Metocar, is a beta‑blocker presented as an oral dosage form for oral use. It is employed to manage high blood pressure, relieve angina, improve outcomes after myocardial infarction, treat certain heart failure patients, and control cardiac arrhythmias.

GNH USA supplies Metocar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Metocar, a selective β1‑adrenergic blocker, is used in several cardiovascular conditions.

- Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Post‑myocardial infarction: improves survival and reduces recurrent ischemic events. - Heart failure: enhances left‑ventricular function and decreases hospitalization. - Cardiac arrhythmias: stabilises heart rhythm by slowing conduction through the AV node.

Metocar may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headed sensation, especially on standing. - Cold extremities: reduced blood flow to hands and feet. - Bradycardia: slower than normal heart rate. - Gastrointestinal upset: nausea, abdominal discomfort. - Sleep disturbances: insomnia or vivid dreams.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: dangerously low blood pressure. - Heart block: impaired electrical conduction in the heart. - Bronchospasm: narrowing of airways, particularly in patients with asthma. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Depression or mood changes: worsening of depressive symptoms.

Before initiating Metocar, consider the following safety measures.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic dysfunction: monitor liver enzymes and consider dose modification. - Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchoconstriction. - Diabetes: monitor blood glucose as beta‑blockers may mask hypoglycaemia symptoms. - Concomitant AV‑node blocking agents: evaluate for additive bradycardia risk. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Metocar can interact with several medication classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may cause excessive bradycardia. - Calcium channel blockers (verapamil, diltiazem): increase risk of heart block and hypotension. - Antihypertensive agents (ACE inhibitors, diuretics): additive blood‑pressure lowering effect.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs (insulin, sulfonylureas): may mask hypoglycaemia signs. - Antidepressants (SSRIs, SNRIs): potential for increased bradycardia. - NSAIDs: may reduce antihypertensive efficacy. - Antithyroid medications: may enhance beta‑blocker effects on heart rate.